

A novel vaccine against *Neisseria gonorrhoeae*

Neisseria gonorrhoeae vaccine using outer membrane vesicles (OMVs) derived from a genetically modified strain of *Neisseria*.

A new strain of gonococcus, produced by replacing the native PorB with analogs from another bacterium to enhance immunogenicity, as new generation outer membrane vesicle (OMV) vaccine.

Applications: Vaccines



Features	Benefits
Simple replacement of <i>Neisseria gonorrhoeae</i> porB gene with <i>Neisseria Meningitidis</i> porB gene	Enhances immunogenicity whilst maintains viability of <i>Neisseria gonorrhoeae</i>
§Deletion of RmpM gene	Increases OMV production which is a key component of OMV vaccines

Patented and Available for

- Co-development
- Consulting

- Licensing

To find out more, contact enquiries@innovation.ox.ac.uk and quote the project number.

The above information is provided 'as is' without conditions or warranties. Oxford University Innovation makes no representation and gives no warranty that it is the owner of the intellectual property rights in the technology described. © Oxford University Innovation Ltd 2026, Buxton Court, 3 West Way, Oxford, OX2 0JB.